The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Tumour-infiltrating CD8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer
Open accessAbstract
BACKGROUND: Tumour-infiltrating lymphocytes (TILs) are known to be associated with response to primary systemic therapy (PST) in breast cancer. This study was conducted to assess the association of TIL subsets with pathological complete response (pCR) after PST in breast cancer in relation to breast cancer subtype, breast cancer stem cell (BCSC) phenotype and epithelial-mesenchymal transition (EMT). METHODS: The pre-chemotherapeutic biopsy specimens of 153 breast cancer patients who underwent surgical resection after anthracycline- or anthracycline/taxane-based PST were analysed. TIL subsets (CD4+, CD8+, and FOXP3+ TILs), BCSC phenotype, and the expression of EMT markers were evaluated by immunohistochemistry and were correlated with pCR after PST. RESULTS: Infiltration of CD4+ and CD8+ T lymphocytes was closely correlated with BCSC phenotype and EMT. High levels of CD4+, CD8+, and FOXP3+ TILs were associated with pCR, and CD8+ TILs were found to be an independent predictive factor for pCR. In addition, CD8+ TILs were associated with pCR irrespective of breast cancer subtype, CD44+/CD24- phenotype, EMT, and chemotherapeutic regimen in subgroup analyses. CONCLUSION: These findings indicate that CD8+ cytotoxic T lymphocytes are a key component of TILs associated with chemo-response and can be used as a reliable predictor of response to anthracycline- or anthracycline/taxane-based PST in breast cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells
Mani, S. A., Guo, W., Liao, M.-J., Eaton, E. N., Ayyanan, A., Zhou, A. Y., Brooks, M., Reinhard, F., Zhang, C. C., Shipitsin, M., et al. (2008) · Cell · doi:10.1016/j.cell.2008.03.027 · Cited by 8,672
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516
Cancer immunoediting: from immunosurveillance to tumor escape
Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Nature Immunology · doi:10.1038/ni1102-991 · Cited by 5,393
Goldhirsch, A., Wood, W. C., Coates, A. S., Gelber, R. D., Thürlimann, B., & Senn, H.-J. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr304 · Cited by 3,836
Liedtke, C., Mazouni, C., Hess, K. R., André, F., Tordai, A., Mejia, J. A., Symmans, W. F., Gonzalez-Angulo, A. M., Hennessy, B., Green, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.4147 · Cited by 2,892
EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer
Singh, A., & Settleman, J. (2010) · Oncogene · doi:10.1038/onc.2010.215 · Cited by 2,545
Sato, E., Olson, S. H., Ahn, J., Bundy, B., Nishikawa, H., Qian, F., Jungbluth, A. A., Frosina, D., Gnjatic, S., Ambrosone, C., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509182102 · Cited by 2,372
The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes
Carey, L. A., Dees, E. C., Sawyer, L., Gatti, L., Moore, D. T., Collichio, F., Ollila, D. W., Sartor, C. I., Graham, M. L., & Perou, C. M. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1109 · Cited by 2,087
Intrinsic Resistance of Tumorigenic Breast Cancer Cells to Chemotherapy
Li, X., Lewis, M. T., Huang, J., Gutierrez, C., Osborne, C. K., Wu, M.-F., Hilsenbeck, S. G., Pavlick, A., Zhang, X., Chamness, G. C., et al. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn123 · Cited by 1,794
Denkert, C., Loibl, S., Noske, A., Roller, M., Müller, B. M., Komor, M., Budczies, J., Darb-Esfahani, S., Kronenwett, R., Hanusch, C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.7370 · Cited by 1,762
DeNardo, D. G., Brennan, D. J., Rexhepaj, E., Ruffell, B., Shiao, S. L., Madden, S. F., Gallagher, W. M., Wadhwani, N., Keil, S. D., Junaid, S. A., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8274.cd-10-0028 · Cited by 1,715
Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death
Casares, N., Pequignot, M. O., Tesniere, A., Ghiringhelli, F., Roux, S., Chaput, N., Schmitt, E., Hamai, A., Hervas-Stubbs, S., Obeid, M., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050915 · Cited by 1,512
Swann, J. B., & Smyth, M. J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31405 · Cited by 1,447
Creighton, C. J., Li, X., Landis, M., Dixon, J. M., Neumeister, V. M., Sjolund, A., Rimm, D. L., Wong, H., Rodriguez, A., Herschkowitz, J. I., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905718106 · Cited by 1,412
Tumor-Infiltrating CD8+Lymphocytes Predict Clinical Outcome in Breast Cancer
Mahmoud, S. M. A., Paish, E. C., Powe, D. G., Macmillan, R. D., Grainge, M. J., Lee, A. H. S., Ellis, I. O., & Green, A. R. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.5037 · Cited by 1,367
Gianni, L., Eiermann, W., Semiglazov, V., Manikhas, A., Lluch, A., Tjulandin, S., Zambetti, M., Vazquez, F., Byakhow, M., Lichinitser, M., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61964-4 · Cited by 1,255
Buzdar, A. U., Ibrahim, N. K., Francis, D., Booser, D. J., Thomas, E. S., Theriault, R. L., Pusztai, L., Green, M. C., Arun, B. K., Giordano, S. H., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.032 · Cited by 1,171
Bear, H. D., Anderson, S., Brown, A., Smith, R., Mamounas, E. P., Fisher, B., Margolese, R., Theoret, H., Soran, A., Wickerham, D. L., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.12.005 · Cited by 1,118
In Situ Cytotoxic and Memory T Cells Predict Outcome in Patients With Early-Stage Colorectal Cancer
Pagès, F., Kirilovsky, A., Mlecnik, B., Asslaber, M., Tosolini, M., Bindea, G., Lagorce, C., Wind, P., Marliot, F., Bruneval, P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.6147 · Cited by 954
Triple negative tumours: a critical review
Reis‐Filho, J. S., & Tutt, A. N. J. (2008) · Histopathology · doi:10.1111/j.1365-2559.2007.02889.x · Cited by 884
The Humoral Immune System Has a Key Prognostic Impact in Node-Negative Breast Cancer
Schmidt, M., Böhm, D., von Törne, C., Steiner, E., Puhl, A., Pilch, H., Lehr, H.-A., Hengstler, J. G., Kölbl, H., & Gehrmann, M. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5206 · Cited by 836
DeNardo, D. G., & Coussens, L. M. (2007) · Breast Cancer Research · doi:10.1186/bcr1746 · Cited by 677
Tanei, T., Morimoto, K., Shimazu, K., Kim, S. J., Tanji, Y., Taguchi, T., Tamaki, Y., & Noguchi, S. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1479 · Cited by 574
The anticancer immune response: indispensable for therapeutic success?
Zitvogel, L., Apetoh, L., Ghiringhelli, F., André, F., Tesniere, A., & Kroemer, G. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35180 · Cited by 573
Liu, S., Lachapelle, J., Leung, S., Gao, D., Foulkes, W. D., & Nielsen, T. O. (2012) · Breast Cancer Research · doi:10.1186/bcr3148 · Cited by 436
Park, S. Y., Lee, H. E., Li, H., Shipitsin, M., Gelman, R., & Polyak, K. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1532 · Cited by 400
Self-citationImmune-Induced Epithelial to Mesenchymal Transition In vivo Generates Breast Cancer Stem Cells
Santisteban, M., Reiman, J. M., Asiedu, M. K., Behrens, M. D., Nassar, A., Kalli, K. R., Haluska, P., Ingle, J. N., Hartmann, L. C., Manjili, M. H., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3343 · Cited by 379
West, N. R., Milne, K., Truong, P. T., Macpherson, N., Nelson, B. H., & Watson, P. H. (2011) · Breast Cancer Research · doi:10.1186/bcr3072 · Cited by 356
Ismael, G., Hegg, R., Muehlbauer, S., Heinzmann, D., Lum, B., Kim, S.-B., Pienkowski, T., Lichinitser, M., Semiglazov, V., Melichar, B., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70329-7 · Cited by 351
Pivotal Role of Innate and Adaptive Immunity in Anthracycline Chemotherapy of Established Tumors
Mattarollo, S. R., Loi, S., Duret, H., Ma, Y., Zitvogel, L., & Smyth, M. J. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0753 · Cited by 333
Ladoire, S., Arnould, L., Apetoh, L., Coudert, B., Martin, F., Chauffert, B., Fumoleau, P., & Ghiringhelli, F. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4491 · Cited by 310
Ono, M., Tsuda, H., Shimizu, C., Yamamoto, S., Shibata, T., Yamamoto, H., Hirata, T., Yonemori, K., Ando, M., Tamura, K., et al. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1554-7 · Cited by 308
Lymphocyte infiltrates as a prognostic variable in female breast cancer
Aaltomaa, S., Lipponen, P., Eskelinen, M., Kosma, V.-M., Marin, S., Alhava, E., & Syrjänen, K. (1992) · European Journal of Cancer · doi:10.1016/0959-8049(92)90134-n · Cited by 286
Chollet, P., Amat, S., Cure, H., de Latour, M., Le Bouedec, G., Mouret-Reynier, M.-A., Ferriere, J.-P., Achard, J.-L., Dauplat, J., & Penault-Llorca, F. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600210 · Cited by 259
Javeed, A., Ashraf, M., Riaz, A., Ghafoor, A., Afzal, S., & Mukhtar, M. M. (2009) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2009.08.009 · Cited by 172
Cancer chemotherapy: not only a direct cytotoxic effect, but also an adjuvant for antitumor immunity
Ménard, C., Martin, F., Apetoh, L., Bouyer, F., & Ghiringhelli, F. (2008) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-008-0505-6 · Cited by 167
Bhargava, R., Beriwal, S., Dabbs, D. J., Özbek, U., Soran, A., Johnson, R. R., Brufsky, A., Lembersky, B. C., & Ahrendt, G. M. (2010) · Cancer · doi:10.1002/cncr.24876 · Cited by 144
Immunoediting of Cancers May Lead to Epithelial to Mesenchymal Transition
Knutson, K. L., Lu, H., Stone, B. C., Reiman, J. M., Behrens, M. D., Prosperi, C., Gad, E. A., Smorlesi, A., & Disis, M. L. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.3.1526 · Cited by 136
Tumor-Associated Lymphocytes Predict Response to Neoadjuvant Chemotherapy in Breast Cancer Patients
Lee, H. J., Seo, J. Y., Ahn, J., Ahn, S. H., & Gong, G. (2013) · Journal of Breast Cancer · doi:10.4048/jbc.2013.16.1.32 · Cited by 132
Self-citationStimulated γδ T Cells Increase the In Vivo Efficacy of Trastuzumab in HER-2+ Breast Cancer
Capietto, A.-H., Martinet, L., & Fournié, J. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1100681 · Cited by 124
Hornychová, H., Melichar, B., Tomšová, M., Mergancová, J., Urminská, H., & Ryška, A. (2008) · Cancer Investigation · doi:10.1080/07357900802098165 · Cited by 113
Immune Promotion of Epithelial-mesenchymal Transition and Generation of Breast Cancer Stem Cells
Reiman, J. M., Knutson, K. L., & Radisky, D. C. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4041 · Cited by 106
Cellular Immunity in Breast Cancer Patients Completing Taxane Treatment
Carson, W. E., Shapiro, C. L., Crespin, T. R., Thornton, L. M., & Andersen, B. L. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-1016-03 · Cited by 94
Oda, N., Shimazu, K., Naoi, Y., et al. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2245-8 · Cited by 86
Active immunotherapy in HER2 overexpressing breast cancer: current status and future perspectives
Milani, A., Sangiolo, D., Montemurro, F., Aglietta, M., & Valabrega, G. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt133 · Cited by 83
Cytotoxic Chemotherapy and CD4+ Effector T Cells: An Emerging Alliance for Durable Antitumor Effects
Ding, Z., & Zhou, G. (2012) · Clinical and Developmental Immunology · doi:10.1155/2012/890178 · Cited by 63
Cited by
Salgado, R., Denkert, C., Demaria, S., Sirtaine, N., Klauschen, F., Pruneri, G., Wienert, S., Van den Eynden, G., Baehner, F. L., Penault-Llorca, F., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdu450 · Cited by 3,113
The clinical role of the TME in solid cancer
Giraldo, N. A., Sanchez-Salas, R., Peske, J. D., Vano, Y., Becht, E., Petitprez, F., Validire, P., Ingels, A., Cathelineau, X., Fridman, W. H., et al. (2019) · British Journal of Cancer · doi:10.1038/s41416-018-0327-z · Cited by 732
Wimberly, H., Brown, J. R., Schalper, K., Haack, H., Silver, M. R., Nixon, C., Bossuyt, V., Pusztai, L., Lannin, D. R., & Rimm, D. L. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0133 · Cited by 397
Tumor-infiltrating B cells signal functional humoral immune responses in breast cancer
Garaud, S., Buisseret, L., Solinas, C., Gu-Trantien, C., de Wind, A., Van den Eynden, G., Naveaux, C., Lodewyckx, J.-N., Boisson, A., Duvillier, H., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.129641 · Cited by 347
Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40
Messenheimer, D. J., Jensen, S. M., Afentoulis, M. E., Wegmann, K. W., Feng, Z., Friedman, D. J., Gough, M. J., Urba, W. J., & Fox, B. A. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2677 · Cited by 321
Metadata
- Authors
- Seo, A. N., Lee, H. J., Kim, E. J., Kim, H. J., Jang, M. H., Lee, H. E., Kim, Y. J., Kim, J. H., & Park, S. Y.
- Venue
- British Journal of Cancer
- Published
- 2013-10-15
- Volume
- 109
- Issue
- 10
- Pages
- 2705-2713
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2313168486
- Cited by
- 317
- References
- 46
- FWCI
- 7.97
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.